In addition, our findings suggest that inhibition of MALT1-mediated CYLD cleavage, through other BCR signalosome inhibitors such as ibrutinib and sotrastaurin, contributes to the anti-tumor effects of these drugs. This evidence concerns the gene BCR and neoplasm.